Pure Global

BECKMAN COULTER COLOMBIA SAS - Authorized Company ProfileBECKMAN COULTER COLOMBIA SAS

Explore comprehensive authorized company profile for BECKMAN COULTER COLOMBIA SAS through Pure Global AI's free Colombia medical device database. This company manufactures 384 medical devices registered with INVIMA across 5 risk classes. Their registration history spans from Jun 14, 2024 to May 07, 2034.

This page provides detailed insights including recent registrations, risk class distribution (I: 145, II: 184, IIa: 8, and more), and complete regulatory information from the official Colombia INVIMA medical device database with bilingual Spanish/English support. Pure Global AI offers free access to Colombia's complete medical device registry.

Free Authorized Company Profile
Powered by Pure Global AI
384 Devices
5 Risk Classes
BECKMAN COULTER COLOMBIA SAS
BECKMAN COULTER COLOMBIA SAS
Authorized Company
384
Total Devices
5
Risk Classes
2024
Earliest
2034
Latest
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Recent Registrations
Latest 20 INVIMA device registrations

MICROSCAN NEG URINE COMBO 95

MICROSCAN NEG URINE COMBO 95

bafd105247c08cbd9f7d24c7f7847e4d

II
May 07, 2034

1. ACCESS NT-PROBNP (REAGENT PACK)

1. ACCESS NT-PROBNP (REAGENT PACK)

7abe55868146b3b3469893096fb8aa49

II
Apr 10, 2034

CD38 (VHH)-ALEXA FLUOR 488

CD38 (VHH)-ALEXA FLUOR 488

ea1905acfacc90ae1fcde9d59b62e7d4

Oct 27, 2033

DAPI VIABILITY DYE

DAPI VIABILITY DYE

4d823b11dd389dbb9e6f74d5da30de0e

Oct 27, 2033

1. CD2-PC7

1. CD2-PC7

67fb60dbd068054d8cde8a32d6d166e0

II
Jul 13, 2033

DXI 9000 ACCESS IMMUNOASSAY ANALYZER - ANALIZADOR DE INMUNOENSAYOS

DXI 9000 ACCESS IMMUNOASSAY ANALYZER - ANALIZADOR DE INMUNOENSAYOS

b1c25318cfa9b28f906d0783091282f2

IIa
Apr 03, 2033

ANNEXIN A5-FITC

ANNEXIN A5-FITC

7648c15c6dd873b29657a7f936deb87c

Mar 29, 2033

1. CD305-PE

1. CD305-PE

dd0d67bf0eeaaafd7e0431edbe6b2143

Mar 29, 2033

10. CD49D-FITC

10. CD49D-FITC

627b2a6834622c7f6592adb753fba0c2

I
Mar 29, 2033

6. ANTI-IL4-PC7

6. ANTI-IL4-PC7

17fa273a35a0643f2df70fae7e1e09d4

I
Mar 29, 2033

7. CD45RA-PE

7. CD45RA-PE

aa39ab94649d4337b8dada0f7444bcf0

I
Mar 29, 2033

4. ANTI-IFN-Y-FITC

4. ANTI-IFN-Y-FITC

8ad1405cc2460e858f856738d05baabc

I
Mar 29, 2033

2. ANTI-TNFA-PE

2. ANTI-TNFA-PE

bccf847288d6f37b2ac02a3caf917631

I
Mar 29, 2033

3. ANTI-IFN-Y-PE

3. ANTI-IFN-Y-PE

77d84bc0fef0d58b0c0e8c6cf7d00769

I
Mar 29, 2033

8. CD79A-PC5.5

8. CD79A-PC5.5

d12f87c5a4fd16138095a9d2b2c39006

I
Mar 29, 2033

9. CD13-PC7

9. CD13-PC7

ff07f1325eff1679b6653123d48cf1a1

I
Mar 29, 2033

5. ANTI-IL-2-FITC

5. ANTI-IL-2-FITC

c3641299bf7303bdabbce580a42fd54c

I
Mar 29, 2033

CELLMEK SPS/ INSTRUMENTO DE PREPARACIÓN DE MUESTRAS

CELLMEK SPS/ SAMPLE PREPARATION INSTRUMENT

ccbd32e709a45a3632f1ddca4f9276b6

I
Nov 03, 2032

MICROSCAN NEG MIC 61

MICROSCAN NEG MIC 61

d788cc06e5dc6b47d2669df25f94df27

II
Apr 25, 2032

CD38-SNV605

CD38-SNV605

5abe4e84bded205e13a34090b704c741

Apr 12, 2032
Risk Class Distribution
Devices by risk class
II
184
47.9% of total
I
145
37.8% of total
III
29
7.6% of total
Unspecified
18
4.7% of total
IIa
8
2.1% of total